A monocentric experience of growth hormone replacement therapy in adult patients.

Annales d'endocrinologie

PubMedID: 24997769

Abdi L, Sahnoun-Fathallah M, Morange I, Albarel F, Castinetti F, Giorgi R, Brue T. A monocentric experience of growth hormone replacement therapy in adult patients. Ann Endocrinol (Paris). 2014;.
To describe the results of growth hormone (GH) therapy in adult GH-deficient patients treated in a tertiary referral center, with a focus on quality of life and adherence.

Retrospective study of patients followed over a total period of 11years. Quality of life (QOL) was assessed by the QOL-Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA) score and adherence to treatment was measured by a specific questionnaire. Clinical, biological, body composition and bone mineralization parameters were also analyzed.

Data from 81 patients were analyzed. After a median treatment duration of 7years, 2/3 of patients reported improved QOL (mean decrease of AGHDA score of 3.0 points, P<0.001). A trend towards more frequent improvement was observed in middle-aged patients, women, childhood-onset GHD, and in patients with initially more impaired QOL. More than 60% of the patients reported continuing treatment without interruption. Seventy percent declared good adherence (=2 missed injections/month). A majority reported enhanced well-being. Additionally, we observed a mean weight increase of 2kg, while fat mass, waist/hip circumference ratio and lipids were unchanged. Bone mineral density was significantly increased at lumbar spine and femoral neck.

Our study confirmed a sustained improvement in quality of life and showed that majority of patients were still on GH treatment after a median duration of 7years.